HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer
E Van Cutsem , YJ Bang , D Otero Reyes , GM Manikhas
5 ( 4) 272 -272
30
2007
Nivolumab bei Sorafenib-naiven und -behandelten Patienten mit fortgeschrittenem hepatozellulärem Karzinom (HCC) CheckMate 040 Studie
J Trojan , TS Crocenzi , AB El-Khoueiry , T Yau
72. Jahrestagung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten mit Sektion Endoskopie – 11. Herbsttagung der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie gemeinsam mit den Arbeitsgemeinschaften der DGAV 55 ( 08)
2017
Ramosetron for the Prevention of Cisplatin-Induced Acute Emesis: A Prospective Randomized Comparison with Granisetron:
YK Kang , YH Park , BY Ryoo , YJ Bang
Journal of International Medical Research 30 ( 3) 220 -229
85
2002
Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay [published erratum appears in Blood 1995 Dec 15;86(12):4710]
Yoon-Koo Kang , Zhirong Zhan , Joanna Regis , M Alvarez
Blood 86 ( 4) 1515 -1524
39
1995
Einfluss makroskopischer Gefäßinvasion (MVI), extrahepatischer Ausbreitung (EHS) und ECOG Performance Status (ECOG PS) auf den Erkrankungsverlauf bei Sorafenib-behandelten Patienten mit fortgeschrittenem hepatozellulärem Karzinom (HCC): Analyse zweier randomisierter, doppelblinder Phase-III-Studien
A Erhardt , J Bruix , AL Cheng , YK Kang
Zeitschrift Fur Gastroenterologie 47 ( 09) 145
2009
1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A
DV Catenacci , H Park , BY Shim , ST Kim
Annals of Oncology 32 S1043 -S1044
9
2021
Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the phase 3 BRISK-PS study
JM Llovet , T Decaens , JL Raoul , E Boucher
Journal of Hepatology 56 S549 -S549
54
2012
Role of elective gastrectomy in patients with localized aggressive primary gastric lymphoma.
MH Ryu , J Huh , DS Heo , YH Park
BLOOD 100 ( 11) 777A -778A
2002
460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers
K Jhaveri , H Han , E Dotan , DY Oh
Annals of Oncology 33 S749 -S750
30
2022
490P Safety and efficacy of tusamitamab ravtansine in patients with colorectal or gastric cancer expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
A Italiano , A Gazzah , J Tabernero , YK Kang
Annals of Oncology 33 S764 -S765
1
2022
HER2 positivity in advanced gastric cancer is comparable to breast cancer
J Leon-Chong , F Lordick , YK Kang , SR Park
Journal of Clinical Oncology 25 ( 18_suppl) 15057 -15057
12
2007
ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
YJ Bang , Eric Van Cutsem , A Feyereislova , Hyun C Chung
Lancet 376 ( 9742) 687 -697
358
2010
LBA82 Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab+ mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18. 2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
JA Ajani , F Lordick , YJ Bang , PC Enzinger
Annals of Oncology 34 S1322 -S1322
2
2023
Health-related Quality of Life in Patients With HER2-positive Advanced Gastric or Gastroesophageal Junction Cancer With High HER2 Expression Levels-Exploratory Analysis of the Phase III ToGA Study
L Shen , YK Kang , M Lichinitser , HC Chung
European Journal of Cancer 47 S231 -S232
2
2011
Trastuzumab with chemotherapy in untreated HER2-positive advanced or metastatic gastric cancer: Efficacy results from the ToGA trial
YJ Bang , YK Kang , HC Chung , L Shen
대한외과학회 학술대회 초록집 386 -387
2
2009
135MO Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab+ mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18. 2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
JA Ajani , F Lordick , YJ Bang , PC Enzinger
Annals of Oncology 34 S1524 -S1525
1
2023
140P Prevalence of claudin-18 isoform 2 (CLDN18. 2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
YJ Bang , L Shen , YK Kang , Y Chao
Annals of Oncology 34 S1527 -S1528
2023
1382P Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo)+ linagliptin (lina) vs ramucirumab (ram)+ paclitaxel (pac) in MORPHEUS-gastric cancer
J Lee , JA Ajani , HC Chung , YK Kang
Annals of Oncology 32 S1047 -S1047
2021
Safety of two different doses of pertuzumab (P) in combination with trastuzumab (T) and chemotherapy (CTx) in patients (pts) with HER2-positive advanced gastric cancer (aGC)
YK Kang , SY Rha , P Tassone , J Barriuso
EUROPEAN JOURNAL OF CANCER 49 S620 -S621
2013
272 Proffered Papers
F Lordick , YJ Bang , YK Kang , D Otero Reyes